Search

Your search keyword '"Ezhov, M."' showing total 335 results
Start Over Author "Ezhov, M."
335 results on '"Ezhov, M."'

1. Lipoprotein(a) and Immunity

Author

Afanasieva, O. I., Arefieva, T. I., Ezhov, M. V., Pokrovsky, S. N., Toth, Peter P., Series Editor, Kostner, Karam, editor, and Kostner, Gerhard M., editor

Published
2023
Full Text
View/download PDF

3. Retrospective Analysis of Lipid-Lowering and Antiplatelet Therapy Regimen by Clinical Decision Support Service Based on Real-World Data from Electronic Medical Records “Intellect 3 Study”

Author

Benimetskaya, K. S., primary, Provatorov, S. I., additional, Ezhov,  M. V., additional, Krivosheev, Y. S., additional, Gavrilko, A. D., additional, Uranov, A. E., additional, Mikheenko, I. L., additional, Kovalev, E. A., additional, Ponomarenko, A. V., additional, Shangina, A. M., additional, Efremova, Yu. E., additional, Kolmakova, T. E., additional, Matveeva, M. A., additional, Dolgusheva, Yu. A., additional, Alekseeva, I. A., additional, Osokina, A. K., additional, Nozadze, D. N., additional, Atyunina, I. V., additional, Paleev, F. N., additional, Meshkova, M. A., additional, Sharapova, Yu. A., additional, and Losik, D. V., additional

Published
2023
Full Text
View/download PDF

10. A five-year follow-up in homozygous familial hypercholesterolemia patients of the Russian familial hypercholesterolemia registry

Author

Chubykina, U., primary, Ezhov, M., additional, Rozhkova, T., additional, Tmoyan, N., additional, Leontyeva, I., additional, Egorov, L., additional, Serebrenitskaya, M., additional, Galimova, L., additional, Sadykova, D., additional, Namitokov, A., additional, Vasiliev, P., additional, and Konstantinov, V., additional

Published
2023
Full Text
View/download PDF

13. Cardiovascular effects of omega-3 polyunsaturated fatty acids: position of omega-3 polyunsaturated fatty acids in Russian and international guidelines. Council of Experts

Author

Mareev, Yu. V., primary, Ezhov, M. V., additional, Villevalde, S. V., additional, Alieva, A. S., additional, Obrezan, A. G., additional, Tarasov, A. V., additional, Panov, A. V., additional, Konstantinov, V. O., additional, Sergienko, I. V., additional, Arutiunov, A. G., additional, Batiushin, M. M., additional, Gurevich, V. S., additional, Tarlovskaya, E. I., additional, Koziolova, N. A., additional, Gromova, O. A., additional, Orlova, Ya. A., additional, Arutyunov, G. P., additional, and Mareev, V. Yu., additional

Published
2023
Full Text
View/download PDF

14. Control of dyslipidemia in the prevention of recurrent ischemic cerebrovascular accidents (expert opinion)

Author

Tanashyan, M. M., primary, Shamalov, N. A., additional, Voznyuk, I. A., additional, Yanishevsky, S. N., additional, Vinogradov, O. I., additional, Khasanova, D. R., additional, Tikhomirova, O. V., additional, Parfenov, V. A., additional, Oshchepkova, E. V., additional, Ezhov, M. V., additional, Gurevich, V. S., additional, and Arkhipov, V. V., additional

Published
2022
Full Text
View/download PDF

16. Focused vascular ultrasound. Consensus of Russian experts

Author

Balakhonova, T. V., primary, Ershova, A. I., additional, Ezhov, M. V., additional, Barbarash, O. L., additional, Bershtein, L. L., additional, Bogachev, V. Yu., additional, Voevoda, M. I., additional, Genkel, V. V., additional, Gurevich, V. S., additional, Duplyakov, D. V., additional, Imaev, T. E., additional, Konovalov, G. A., additional, Kosmacheva, E. D., additional, Lobastov, K. V., additional, Mitkova, M. D., additional, Nikiforov, V. S., additional, Rotar, O. P., additional, Suchkov, I. A., additional, Yavelov, I. S., additional, Mitkov, V. V., additional, Akchurin, R. S., additional, Drapkina, O. M., additional, and Boytsov, S. A., additional

Published
2022
Full Text
View/download PDF

23. Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology

Author

Arutyunov, A. G., primary, Seferovic, P., additional, Bakulin, I. G., additional, Bakulina, N. V., additional, Batyushin, M. M., additional, Boldina, M. V., additional, Krstačić, G., additional, Macut, Dj., additional, Salukhov, V. V., additional, Shimosawa, T., additional, Shustov, V. V., additional, Tarlovskaya, E. I., additional, Vrtovec, B., additional, Wanner, C., additional, Aisanov, Z. R., additional, Arutyunov, G. P., additional, Avdeev, S. N., additional, Babin, A. P., additional, Cattaneo, M., additional, Chesnikova, A. I., additional, Ezhov, M. V., additional, Kamilova, U. K., additional, Koziolova, N. A., additional, Lopatin, Yu. M., additional, Mitkovskaya, N. P., additional, Morais, J., additional, Galstyan, G. R., additional, Sarybaev, A. Sh., additional, Sugraliev, A. B., additional, Yavelov, I. S., additional, Essaian, A. M., additional, Zolotovskaya, I. A., additional, Zhangelova, Sh. B., additional, Zyryanov, S. K., additional, Melnikov, E. S., additional, Bashkinov, R. A., additional, and Shlyakhto, E. V., additional

Published
2021
Full Text
View/download PDF

27. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)

Author

Zhubi-Bakija, F., Bajraktari, G., Bytyci, I., Mikhailidis, D. P., Henein, M. Y., Latkovskis, G., Rexhaj, Z., Zhubi, E., Banach, M., Alnouri, F., Amar, F., Atanasov, A. G., Bartlomiejczyk, M. A., Bjelakovic, B., Bruckert, E., Cafferata, A., Ceska, R., Cicero, A. F. G., Collet, X., Descamps, O., Djuric, D., Durst, R., Ezhov, M. V., Fras, Z., Gaita, D., Hernandez, A. V., Jones, S. R., Jozwiak, J., Kakauridze, N., Katsiki, N., Khera, A., Kostner, K., Kubilius, R., Mancini, G. B. J., Marais, A. D., Martin, S. S., Martinez, J. A., Mazidi, M., Mirrakhimov, E., Miserez, A. R., Mitchenko, O., Moriarty, P. M., Nabavi, S. M., Nair, D., Panagiotakos, D. B., Paragh, G., Pella, D., Penson, P. E., Petrulioniene, Z., Pirro, M., Postadzhiyan, A., Puri, R., Reda, A., Reiner, Riadh, J., Richter, D., Rizzo, M., Ruscica, M., Sahebkar, A., Sattar, N., Serban, M. -C., Shehab, A. M. A., Shek, A. B., Sirtori, C. R., Stefanutti, C., Tomasik, T., Toth, P. P., Viigimaa, M., Vinereanu, D., Vohnout, B., von Haehling, S., Vrablik, M., Wong, N. D., Yeh, H. -I., Zhisheng, J., Zirlik, A., Zhubi-Bakija F, Bajraktari G, Bytyçi I, Mikhailidis DP, Henein MY, Latkovskis G, Rexhaj Z, Zhubi E, Banach M, International Lipid Expert Panel (ILEP), Cicero AFG, Zhubi-Bakija F., Bajraktari G., Bytyci I., Mikhailidis D.P., Henein M.Y., Latkovskis G., Rexhaj Z., Zhubi E., Banach M., Alnouri F., Amar F., Atanasov A.G., Bartlomiejczyk M.A., Bjelakovic B., Bruckert E., Cafferata A., Ceska R., Cicero A.F.G., Collet X., Descamps O., Djuric D., Durst R., Ezhov M.V., Fras Z., Gaita D., Hernandez A.V., Jones S.R., Jozwiak J., Kakauridze N., Katsiki N., Khera A., Kostner K., Kubilius R., Mancini G.B.J., Marais A.D., Martin S.S., Martinez J.A., Mazidi M., Mirrakhimov E., Miserez A.R., Mitchenko O., Moriarty P.M., Nabavi S.M., Nair D., Panagiotakos D.B., Paragh G., Pella D., Penson P.E., Petrulioniene Z., Pirro M., Postadzhiyan A., Puri R., Reda A., Reiner, Riadh J., Richter D., Rizzo M., Ruscica M., Sahebkar A., Sattar N., Serban M.-C., Shehab A.M.A., Shek A.B., Sirtori C.R., Stefanutti C., Tomasik T., Toth P.P., Viigimaa M., Vinereanu D., Vohnout B., von Haehling S., Vrablik M., Wong N.D., Yeh H.-I., Zhisheng J., Zirlik A., and UCL - (SLuc) Service de pathologie cardiovasculaire

Subjects
Adult, Male, Dietary protein, Weight loss, Cardiometabolic Risk Factors, food and beverages, Middle Aged, Recommended Dietary Allowances, Cardiovascular disease, Plant Proteins, Dietary, Cardiovascular disease, Cholesterol, Dietary protein, Metabolic syndrome, Weight loss, Adult, Aged, Animal Proteins, Dietary, Cardiometabolic Risk Factors, Cardiovascular Diseases, Diet, Healthy, Expert Testimony, Female, Humans, Male, Middle Aged, Plant Proteins, Dietary, Young Adult, Recommended Dietary Allowances, Metabolic syndrome, Young Adult, Cholesterol, Cardiovascular Diseases, Animal Proteins, Dietary, Humans, Female, Diet, Healthy, Expert Testimony, Aged
Abstract

Proteins play a crucial role in metabolism, in maintaining fluid and acid-base balance and antibody synthesis. Dietary proteins are important nutrients and are classified into: 1) animal proteins (meat, fish, poultry, eggs and dairy), and, 2) plant proteins (legumes, nuts and soy). Dietary modification is one of the most important lifestyle changes that has been shown to significantly decrease the risk of cardiovascular (CV) disease (CVD) by attenuating related risk factors. The CVD burden is reduced by optimum diet through replacement of unprocessed meat with low saturated fat, animal proteins and plant proteins. In view of the available evidence, it has become acceptable to emphasize the role of optimum nutrition to maintain arterial and CV health. Such healthy diets are thought to increase satiety, facilitate weight loss, and improve CV risk. Different studies have compared the benefits of omnivorous and vegetarian diets. Animal protein related risk has been suggested to be greater with red or processed meat over and above poultry, fish and nuts, which carry a lower risk for CVD. In contrast, others have shown no association of red meat intake with CVD. The aim of this expert opinion recommendation was to elucidate the different impact of animal vs vegetable protein on modifying cardiometabolic risk factors. Many observational and interventional studies confirmed that increasing protein intake, especially plant-based proteins and certain animal-based proteins (poultry, fish, unprocessed red meat low in saturated fats and low-fat dairy products) have a positive effect in modifying cardiometabolic risk factors. Red meat intake correlates with increased CVD risk, mainly because of its non-protein ingredients (saturated fats). However, the way red meat is cooked and preserved matters. Thus, it is recommended to substitute red meat with poultry or fish in order to lower CVD risk. Specific amino acids have favourable results in modifying major risk factors for CVD, such as hypertension. Apart from meat, other animal-source proteins, like those found in dairy products (especially whey protein) are inversely correlated to hypertension, obesity and insulin resistance.

Published
2021

28. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021)

Author

Chazova, I. E., primary, Shestakova, M. V., additional, Zhernakova, Yu. V., additional, Blinova, N. V., additional, Markova, T. N., additional, Mazurina, N. V., additional, Ezhov, M. V., additional, Tereshchenko, S. N., additional, Zhirov, I. V., additional, Komarov, A. L., additional, Mironova, O. Yu., additional, Yuricheva, Yu. A., additional, Suhareva, O. Yu., additional, Kislyak, O. A., additional, Mkrtumyan, A. M., additional, Podzolkov, V. I., additional, Azizov, V. A., additional, Zelveyan, P. A., additional, Grigorenko, E. A., additional, Rahimov, Z. Ya., additional, Sarybaev, A. Sh., additional, Kasymova, S. D., additional, and Narzullaeva, A. R., additional

Published
2021
Full Text
View/download PDF

31. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

Author

Cicero A. F. G., Fogacci F., Hernandez A. V., Banach M., Alnouri F., Amar F., Atanasov A. G., Bajraktari G., Bartlomiejczyk M. A., Bjelakovic B., Bruckert E., Bielecka-Dabrowa A., Cafferata A., Ceska R., Collet X., Descamps O., Devaki N., Djuric D., Durst R., Ezhov M. V., Fras Z., Gaita D., von Haehling S., Jones S. R., Jozwiak J., Kakauridze N., Katsiki N., Khera A., Kostner K., Kubilius R., Latkovskis G., Mancini G. B. J., Marais A. D., Martin S. S., Martinez J. A., Mazidi M., Mikhailidis D. P., Mirrakhimov E., Miserez A. R., Mitchenko O., Moriarty P., Nabavi S. M., Panagiotakos D. B., Paragh G., Pella D., Penson P. E., Petrulioniene Z., Pirro M., Postadzhiyan A., Puri R., Reda A., Reiner Z., Riadh J., Richter D., Rizzo M., Ruscica M., Sahebkar A., Sattar N., Serban M. C., Shehab A. M. A., Shek A. B., Sirtori C. R., Stefanutti C., Tomasik T., Toth P. P., Viigimaa M., Vinereanu D., Vohnout B., Vrablik M., Wong N. D., Yeh H. I., Zhisheng J., Zirlik A., Cicero A.F.G., Fogacci F., Hernandez A.V., Banach M., Alnouri F., Amar F., Atanasov A.G., Bajraktari G., Bartlomiejczyk M.A., Bjelakovic B., Bruckert E., Bielecka-Dabrowa A., Cafferata A., Ceska R., Collet X., Descamps O., Devaki N., Djuric D., Durst R., Ezhov M.V., Fras Z., Gaita D., von Haehling S., Jones S.R., Jozwiak J., Kakauridze N., Katsiki N., Khera A., Kostner K., Kubilius R., Latkovskis G., Mancini G.B.J., Marais A.D., Martin S.S., Martinez J.A., Mazidi M., Mikhailidis D.P., Mirrakhimov E., Miserez A.R., Mitchenko O., Moriarty P., Nabavi S.M., Panagiotakos D.B., Paragh G., Pella D., Penson P.E., Petrulioniene Z., Pirro M., Postadzhiyan A., Puri R., Reda A., Reiner Z., Riadh J., Richter D., Rizzo M., Ruscica M., Sahebkar A., Sattar N., Serban M.C., Shehab A.M.A., Shek A.B., Sirtori C.R., Stefanutti C., Tomasik T., Toth P.P., Viigimaa M., Vinereanu D., Vohnout B., Vrablik M., Wong N.D., Yeh H.I., Zhisheng J., Zirlik A., Wierzbicki, Anthony, Penson, P, and Cicero AF, Fogacci F, Hernandez AV, Banach M

Subjects
Apolipoprotein B, Publication Ethics, 030204 cardiovascular system & hematology, Cardiovascular, Gastroenterology, Lipoprotein particle, Medical and Health Sciences, Biochemistry, chemistry.chemical_compound, Database and Informatics Methods, 0302 clinical medicine, Mathematical and Statistical Techniques, Anticholesteremic Agents, Apolipoproteins B, Cholesterol, Cholesterol, LDL, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Dicarboxylic Acids, Fatty Acids, Humans, Hypercholesterolemia, Peptide Fragments, Randomized Controlled Trials as Topic, Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel, Medicine and Health Sciences, Dicarboxylic Acids, 030212 general & internal medicine, Database Searching, Research Integrity, Randomized Controlled Trials as Topic, medicine.diagnostic_test, biology, Anticholesteremic Agents, Statistics, Fatty Acids, Drugs, General Medicine, Metaanalysis, Serious Mental Illness, Lipids, Phase III as Topic, Mental Health, Cholesterol, Physical Sciences, Medicine, Research Article, medicine.medical_specialty, RM, Science Policy, Lipoproteins, Hypercholesterolemia, Bempedoic acid, hypercholesterolemia, lipid profile, hsCRP, Research and Analysis Methods, LDL, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Internal medicine, General & Internal Medicine, medicine, Humans, Clinical Trials, Statistical Methods, Apolipoproteins B, Pharmacology, Plasma Proteins, business.industry, Phase II as Topic, Statins, Biology and Life Sciences, Proteins, Odds ratio, Cholesterol, LDL, Confidence interval, Peptide Fragments, chemistry, Clinical Trials, Phase III as Topic, biology.protein, Uric acid, Creatine kinase, Lipid profile, business, Digestive Diseases, Mathematics
Abstract

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-sensitivity C-reactive protein (hsCRP) serum concentration were expressed as mean differences (MDs) and 95% confidence intervals (CIs). For safety analyses, odds ratios (ORs) and 95% CIs were calculated using the Mantel–Haenszel method. Bempedoic acid significantly reduced total cholesterol (MD −14.94%; 95% CI −17.31%, −12.57%; p < 0.001), non-high-density lipoprotein cholesterol (MD −18.17%; 95% CI −21.14%, −15.19%; p < 0.001), low-density lipoprotein cholesterol (MD −22.94%; 95% CI −26.63%, −19.25%; p < 0.001), low-density lipoprotein particle number (MD −20.67%; 95% CI −23.84%, −17.48%; p < 0.001), apolipoprotein B (MD −15.18%; 95% CI −17.41%, −12.95%; p < 0.001), high-density lipoprotein cholesterol (MD −5.83%; 95% CI −6.14%, −5.52%; p < 0.001), high-density lipoprotein particle number (MD −3.21%; 95% CI −6.40%, −0.02%; p = 0.049), and hsCRP (MD −27.03%; 95% CI −31.42%, −22.64%; p < 0.001). Bempedoic acid did not significantly modify triglyceride level (MD −1.51%; 95% CI −3.75%, 0.74%; p = 0.189), very-low-density lipoprotein particle number (MD 3.79%; 95% CI −9.81%, 17.39%; p = 0.585), and apolipoprotein A-1 (MD −1.83%; 95% CI −5.23%, 1.56%; p = 0.290). Treatment with bempedoic acid was positively associated with an increased risk of discontinuation of treatment (OR 1.37; 95% CI 1.06, 1.76; p = 0.015), elevated serum uric acid (OR 3.55; 95% CI 1.03, 12.27; p = 0.045), elevated liver enzymes (OR 4.28; 95% CI 1.34, 13.71; p = 0.014), and elevated creatine kinase (OR 3.79; 95% CI 1.06, 13.51; p = 0.04), though it was strongly associated with a decreased risk of new onset or worsening diabetes (OR 0.59; 95% CI 0.39, 0.90; p = 0.01). The main limitation of this meta-analysis is related to the relatively small number of individuals involved in the studies, which were often short or middle term in length. Conclusions Our results show that bempedoic acid has favorable effects on lipid profile and hsCRP levels and an acceptable safety profile. Further well-designed studies are needed to explore its longer-term safety., Maciej Banach and colleagues discuss the efficacy and safety of bempedoic acid, a drug that designed to lower LDL-C levels., Author summary Why was this study done? Lowering low-density lipoprotein cholesterol (LDL-C) is effective for reducing cardiovascular events over time. A number of phase II and phase III randomized controlled trials (RCTs) are already available showing encouraging results of bempedoic acid treatment on LDL-C. We aimed to perform a systematic review and meta-analysis on the clinical evidence available to date to better define the efficacy and tolerability profile of treatment with bempedoic acid. What did the researchers do and find? In this analysis of bempedoic acid that included 10 randomized clinical trials (n = 3,788 patients) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]), we confirmed that bempedoic acid significantly reduced total cholesterol (by 15%), non-high-density lipoprotein cholesterol (by 18.2%), LDL-C (by 22.9%), low-density lipoprotein particle number (by 20.7%), apolipoprotein B (by 15.2%), and high-sensitivity C-reactive protein (hsCRP) (by 27%), while negatively affecting serum levels of high-density lipoprotein cholesterol (−5.8%) and high-density lipoprotein particle number (−3.2%). Our results also confirmed that the therapy is overall safe and well tolerated, with no significant increase of serious adverse effects. What do these findings mean? The current meta-analysis demonstrates the multiple positive effects of bempedoic acid on lipid profile and hsCRP serum levels, as well as acceptable safety profile. This could be relevant in a setting where statin intolerance is very frequent and the LDL-C target suggested by international guidelines for dyslipidemia management is hard to achieve with standard therapies. An ongoing long-term cardiovascular outcomes trial will answer questions on the effect of bempedoic acid on cardiovascular events and mortality as well as on the drug’s safety issues.

Published
2020

32. 2019 ESC/EAS Guidelines for the management of dyslipidaemias

Author

Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., Chapman, M.J., Backer, G.G. de, Delgado, V., Ference, B.A., Graham, I.M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T.R., Riccardi, G., Richter, D.J., Sabatine, M.S., Taskinen, M.R., Tokgozoglu, L., Wiklund, O., Nibouche, D., Zelveian, P.H., Siostrzonek, P., Najafov, R., Borne, P. van de, Pojskic, B., Postadzhiyan, A., Kypris, L., Spinar, J., Larsen, M.L., Eldin, H.S., Viigimaa, M., Strandberg, T.E., Ferrieres, J., Agladze, R., Laufs, U., Rallidis, L., Bajnok, L., Gudjonsson, T., Maher, V., Henkin, Y., Gulizia, M.M., Mussagaliyeva, A., Bajraktari, G., Kerimkulova, A., Latkovskis, G., Hamoui, O., Slapikas, R., Visser, L., Dingli, P., Ivanov, V., Boskovic, A., Nazzi, M., Visseren, F., Mitevska, I., Retterstol, K., Jankowski, P., Fontes-Carvalho, R., Gaita, D., Ezhov, M., Foscoli, M., Giga, V., Pella, D., Fras, Z., Isla, L.P. de, Hagstrom, E., Lehmann, R., Abid, L., Ozdogan, O., Mitchenko, O., Patel, R.S., Windecker, S., Aboyans, V., Collet, J.P., Dean, V., Fitzsimons, D., Gale, C.P., Grobbee, D., Halvorsen, S., Hindricks, G., Iung, B., Juni, P., Katus, H.A., Leclercq, C., Lettino, M., Lewis, B.S., Merkely, B., Mueller, C., Petersen, S., Petronio, A.S., Roffi, M., Shlyakhto, E., Simpson, I.A., Sousa-Uva, M., Touyz, R.M., Task Force Members, ESC Natl Cardiac Soc, and ESC Committee Practice Guidelines

Published
2020

37. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)

Author

Kukharchuk, V. V., primary, Ezhov, M. V., additional, Sergienko, I. V., additional, Arabidze, G. G., additional, Balakhonova, T. V., additional, Gurevich, V. S., additional, Zelveyan, P. A., additional, Murataliev, T. M., additional, Myrzakhmetova, G. Sh., additional, Sudzhaeva, O. A., additional, Shek, A. B., additional, Azizov, V. A., additional, Gornyakova, N. B., additional, Kachkovsky, M. A., additional, Malyshev, P. P., additional, Pokrovsky, S. N., additional, Sokolov, A. A., additional, Sumarokov, A. B., additional, Obrezan, A. G., additional, Shaposhnik, I. I., additional, Antsiferov, M. B., additional, Ansheles, A. A., additional, Aronov, D. M., additional, Akhmedzhanov, N. M., additional, Barbarash, O. L., additional, Boytsov, S. A., additional, Bubnova, M. G., additional, Voevoda, M. I., additional, Galstyan, G. R., additional, Galyavich, A. S., additional, Drapkina, O. M., additional, Duplyakov, D. V., additional, Eregin, S. Ya., additional, Karpov, R. S., additional, Karpov, Yu. A., additional, Koziolova, N. A., additional, Konovalov, G. A., additional, Konstantinov, V. O., additional, Kosmacheva, E. D., additional, Nedogoda, S. V., additional, Olejnikov, V. E., additional, Ragino, Yu. I., additional, Skibickij, V. V., additional, Smolenskaya, O. G., additional, Halimov, Yu. Sh., additional, Chazova, I. E., additional, Filippov, A. E., additional, Shestakova, M. V., additional, and Yakushin, S. S., additional

Published
2020
Full Text
View/download PDF

39. The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion)

Author

Ezhov, M. V., primary, Catapano, A., additional, Escobar, C., additional, Kukharchuk, V. V., additional, Voevoda, M. I., additional, Drapkina, O. M., additional, Shalnova, S. A., additional, Starodubova, A. V., additional, Gurevich, V. S., additional, Shaposhnik, I. I., additional, Bolshakova, O. O., additional, Oynotkinova, O. S., additional, and Alieva, A. S., additional

Published
2020
Full Text
View/download PDF

42. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Author

Banach, M., RIZZO, Manfredi, Toth, P., Farnier, M., Davidson, M., Al Rasadi, K., Aronow, W., Athyros, V., Djuric, D., Ezhov, M., Greenfield, R., Hovingh, G., Kostner, K., Serban, C., Lighezan, D., Fras, Z., Moriarty, P., Muntner, P., Goudev, A., Ceska, R., Nicholls, S., Broncel, M., NIKOLIC, Dragana, Pella, D., Puri, R., Rysz, J., Wong, N., Bajnok, L., Jones, S., Ray, K., Mikhailidis, D., Banach, M., Rizzo, M., Toth, P., Farnier, M., Davidson, M., Al-Rasadi, K., Aronow, W., Athyros, V., Djuric, D., Ezhov, M., Greenfield, R., Hovingh, G., Kostner, K., Serban, C., Lighezan, D., Fras, Z., Moriarty, P., Muntner, P., Goudev, A., Ceska, R., Nicholls, S., Broncel, M., Nikolic, D., Pella, D., Puri, R., Rysz, J., Wong, N., Bajnok, L., Jones, S., Ray, K., Mikhailidis, D., ACS - Amsterdam Cardiovascular Sciences, and Vascular Medicine

Subjects
CHRONIC KIDNEY-DISEASE, RANDOMIZED CONTROLLED-TRIALS, Muscle symptom, PLACEBO-CONTROLLED TRIAL, Medicine, General & Internal, Muscular Diseases, Cardiovascular Disease, General & Internal Medicine, Definition, Muscle symptoms, Risk factors, Statin intolerance, Cardiovascular Diseases, Dyslipidemias, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Pharmacology (medical), Medicine (all), definition, risk factors, CORONARY-HEART-DISEASE, THROMBOTIC THROMBOCYTOPENIC PURPURA, cardiovascular diseases, FATTY LIVER-DISEASE, PRIMARY BILIARY-CIRRHOSIS, Science & Technology, Muscular Disease, POST-HOC ANALYSIS, nutritional and metabolic diseases, 1103 Clinical Sciences, COA-REDUCTASE INHIBITORS, Dyslipidemia, DENSITY-LIPOPROTEIN CHOLESTEROL, muscle symptoms, lipids (amino acids, peptides, and proteins), Hydroxymethylglutaryl-CoA Reductase Inhibitor, Risk factor, Position Paper, Life Sciences & Biomedicine, Human, statin intolerance
Abstract

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.

Published
2015

44. The Role of Nutraceuticals in Statin Intolerant Patients

Author

Banach, M. Patti, A.M. Giglio, R.V. Cicero, A.F.G. Atanasov, A.G. Bajraktari, G. Bruckert, E. Descamps, O. Djuric, D.M. Ezhov, M. Fras, Z. von Haehling, S. Katsiki, N. Langlois, M. Latkovskis, G. Mancini, G.B.J. Mikhailidis, D.P. Mitchenko, O. Moriarty, P.M. Muntner, P. Nikolic, D. Panagiotakos, D.B. Paragh, G. Paulweber, B. Pella, D. Pitsavos, C. Reiner, Ž. Rosano, G.M.C. Rosenson, R.S. Rysz, J. Sahebkar, A. Serban, M.-C. Vinereanu, D. Vrablík, M. Watts, G.F. Wong, N.D. Rizzo, M. International Lipid Expert Panel (ILEP)

Subjects
lipids (amino acids, peptides, and proteins)
Abstract

Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non–lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction. © 2018 American College of Cardiology Foundation

Published
2018

45. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Author

Vallejo-Vaz, A.J. Marco, M.D. Stevens, C.A.T. Akram, A. Freiberger, T. Hovingh, G.K. Kastelein, J.J.P. Mata, P. Raal, F.J. Santos, R.D. Soran, H. Watts, G.F. Abifadel, M. Aguilar-Salinas, C.A. Al-Khnifsawi, M. Alkindi, F.A. Alnouri, F. Alonso, R. Al-Rasadi, K. Al-Sarraf, A. Ashavaid, T.F. Binder, C.J. Bogsrud, M.P. Bourbon, M. Bruckert, E. Chlebus, K. Corral, P. Descamps, O. Durst, R. Ezhov, M. Fras, Z. Genest, J. Groselj, U. Harada-Shiba, M. Kayikcioglu, M. Lalic, K. Lam, C.S.P. Latkovskis, G. Laufs, U. Liberopoulos, E. Lin, J. Maher, V. Majano, N. Marais, A.D. März, W. Mirrakhimov, E. Miserez, A.R. Mitchenko, O. Nawawi, H.M. Nordestgaard, B.G. Paragh, G. Petrulioniene, Z. Pojskic, B. Postadzhiyan, A. Reda, A. Reiner, Ž. Sadoh, W.E. Sahebkar, A. Shehab, A. Shek, A.B. Stoll, M. Su, T.-C. Subramaniam, T. Susekov, A.V. Symeonides, P. Tilney, M. Tomlinson, B. Truong, T.-H. Tselepis, A.D. Tybjærg-Hansen, A. Vázquez-Cárdenas, A. Viigimaa, M. Vohnout, B. Widén, E. Yamashita, S. Banach, M. Gaita, D. Jiang, L. Nilsson, L. Santos, L.E. Schunkert, H. Tokgözoğlu, L. Car, J. Catapano, A.L. Ray, K.K. Schreier, L. Pang, J. Dieplinger, H. Hanauer-Mader, G. Desutter, J. Langlois, M. Mertens, A. Rietzschel, E. Wallemacq, C. Isakovic, D. Dzankovic, A.M. Obralija, J. Pojskic, L. Sisic, I. Stimjanin, E. Torlak, V.A. Jannes, C.E. Krieger, J.E. Pereira, A.C. Ruel, I. Asenjo, S. Cuevas, A. Pećin, I. Miltiadous, G. Panayiotou, A.G. Vrablik, M. Benn, M. Heinsar, S. Béliard, S. Gouni-Berthold, I. Hengstenberg, W. Julius, U. Kassner, U. Klose, G. König, C. König, W. Otte, B. Parhofer, K. Schatz, U. Schmidt, N. Steinhagen-Thiessen, E. Vogt, A. Antza, C. Athyros, V. Bilianou, E. Boufidou, A. Chrousos, G. Elisaf, M. Garoufi, A. Katsiki, N. Kolovou, G. Kotsis, V. Rallidis, L. Rizos, C. Skalidis, E. Skoumas, I. Tziomalos, K. Shawney, J.P.S. Abbaszadegan, M.R. Aminzadeh, M. Hosseini, S. Mobini, M. Vakili, R. Zaeri, H. Agar, R. Boran, G. Colwell, N. Crowley, V. Durkin, M. Griffin, D. Kelly, M. Rakovac-Tisdall, A. Bitzur, R. Cohen, H. Eliav, O. Ellis, A. Gavish, D. Harats, D. Henkin, Y. Knobler, H. Leavit, L. Leitersdorf, E. Schurr, D. Shpitzen, S. Szalat, A. Arca, M. Averna, M. Bertolini, S. Calandra, S. Tarugi, P. Erglis, A. Gilis, D. Nesterovics, G. Saripo, V. Upena-Roze, A. Elbitar, S. Jambart, S. Khoury, P.E. Gargalskaite, U. Kutkiene, S. Al-Khateeb, A. An, C.Y. Ismail, Z. Kasim, S. Ibrahim, K.S. Radzi, A.B.M. Kasim, N.A. Nor, N.S.M. Ramli, A.S. Razak, S.A. Muid, S. Rosman, A. Sanusi, A.R. Razman, A.Z. Nazli, S.A. Kek, T.L. Azzopardi, C. Aguilar Salinas, C.A. Galán, G. Rubinstein, A. Magaña-Torres, M.T. Martagon, A. Mehta, R. Wittekoek, M.E. Isara, A.R. Obaseki, D.E. Ohenhen, O.A. Holven, K.B. Gruchała, M. Baranowska, M. Borowiec-Wolny, J. Gilis-Malinowska, N. Michalska-Grzonkowska, A. Pajkowski, M. Parczewska, A. Romanowska-Kocejko, M. Stróżyk, A. Żarczyńska-Buchowiecka, M. Kleinschmidt, M. Alves, A.C. Medeiros, A.M. Ershova, A. Korneva, V. Kuznetsova, T. Malyshev, P. Meshkov, A. Rozhkova, T. Popovic, L. Lukac, S.S. Stosic, L. Rasulic, I. Lalic, N.M. Chua, T.S.J. Ting, S.P.L. Raslova, K. Battelino, T. Cevc, M. Jug, B. Kovac, J. Podkrajsek, K.T. Sustar, U. Trontelj, K.J. Marais, D. Isla, L.P. Martin, F.J. Charng, M.-J. Chen, P.-L. Kayikçioglu, M. Dell’oca, N. Fernández, G. Ressia, A. Reyes, X. Zelarayan, M. Alieva, R.B. Hoshimov, S.U. Nizamov, U.I. Kurbanov, R.D. Lima-Martínez, M.M. Nguyen, M.-N.T. Do, D.-L. Kim, N.-T. Le, T.-T. Le, H.-A.

Abstract

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V.

Published
2018

46. Association Between Lipoprotein(a) and Risk Factors of Atherosclerosis in Russian Population (Data of Observational ESSE-RF study)

Author

Shalnova, S. A., primary, Ezhov, M. V., additional, Metelskaya, V. A., additional, Evstifeeva, S. E., additional, Tarasov, V. I., additional, Muromtseva, G. A., additional, Balanova, Yu. A., additional, Imaeva, A. E., additional, Kapustina, A. V., additional, Shabunova, A. A., additional, Belova, O. A., additional, Trubacheva, I. A., additional, Efanov, A. Y., additional, Astakhova, Z. T., additional, Kulakova, N. V., additional, Boytsov, S. A., additional, and Drapkina, O. M., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results